Featured Image

Strategic Partners

It will be necessary for Axonis to test candidate therapies in an established primate model. The exact studies will be defined based on discussions with the FDA. Potential investment and eventual FDA approval will be facilitated by proving that PTEN inhibition is successful in primates. These studies will be executed through contractual arrangements between Axonis and entities that have developed primates SCI models. Pending discussions with the FDA, Axonis will use contract research organizations (CRO’s) for required safety testing, bio-distribution assessments and other contractors when needed.

The Christopher and Dana Reeve Foundation has established the North American Clinical Trials Network (NACTN) as one way to bring promising therapies for SCI out of the laboratory and into clinical trials in a manner that provides strong evidence of effectiveness and safety. NACTN supports a network of eleven clinical centers that conduct clinical trials that maximize patient safety while gathering valid, meaningful data to speed the delivery of new therapies to patients. The founders of Axonis have decades long relationships with the Christopher and Dana Reeve Foundation. NACTN provides an excellent potential clinical trial network for the Company to test PTEN inhibition in humans with SCI.

With proof of concept in humans, larger partners have indicated interest in partnering with Axonis to help move this therapy to SCI acute and chronic patients.

The founders of Axonis have decades long relationships with the Christopher and Dana Reeve Foundation. NACTN provides an excellent potential clinical trial network for the Company to test PTEN inhibition in humans with SCI.

 

Scroll Up